Alkermes (ALKS) Cash from Financing Activities (2010 - 2026)

Alkermes' (ALKS) quarterly Cash from Financing Activities came in at $1.5 billion in Q1 2026, up 197292.1% year-on-year from N/an in Q1 2025, and up 13412.82% on a QoQ basis from $10.9 million in Q4 2025.

Alkermes (ALKS) Cash from Financing Activities (2010 - 2026) Analysis & Trends

Alkermes (ALKS) has 17 years of Cash from Financing Activities data on file, last reported at $1.5 billion in Q1 2026.

  • On a quarterly basis, Cash from Financing Activities rose 197292.1% year-over-year to $1.5 billion in Q1 2026; TTM through Mar 2026 was $1.5 billion, a 412.53% increase from a year earlier, with the FY2025 full-year figure at $12.4 million, up 102.51% from the prior year.
  • Cash from Financing Activities for Q1 2026 stood at $1.5 billion, up from $10.9 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for ALKS reached as high as $1.5 billion in Q1 2026 and fell as low as -$281.7 million in Q4 2024.
  • Historically, Cash from Financing Activities has averaged $41.3 million across 5 years, with a median of -$212000.0 in 2022.
  • Across the five-year window, Cash from Financing Activities plunged 101928.41% in 2023 and surged 197292.1% in 2026, its largest moves.
  • Year by year, Cash from Financing Activities stood at -$271000.0 in 2022, then plunged by 101928.41% to -$276.5 million in 2023, then dropped by 1.87% to -$281.7 million in 2024, then soared by 103.87% to $10.9 million in 2025, then jumped by 13412.82% to $1.5 billion in 2026.
  • Per Business Quant data, the three most recent Cash from Financing Activities figures were $1.5 billion in Q1 2026, $10.9 million in Q4 2025, and $315000.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 13.00 Mn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn -840.00 Mn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn -494.13 Mn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn -1.48 Bn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn -203.80 Mn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn -86.10 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn -65.00 Mn
10 Alkermes 9.72 Bn 9.21 Bn 331.33 Mn 1.47 Bn

Historic Data

Download Data
DateValue
Mar 31, 2026 1.47 Bn
Mar 31, 2026 1.47 Bn
Dec 31, 2025 10.91 Mn
Dec 31, 2025 10.91 Mn
Sep 30, 2025 315,000.00
Sep 30, 2025 315,000.00
Jun 30, 2025 405,000.00
Jun 30, 2025 405,000.00
Mar 31, 2025 747,000.00
Mar 31, 2025 747,000.00
Dec 31, 2024 -281.67 Mn
Dec 31, 2024 -281.67 Mn
Sep 30, 2024 -111.11 Mn
Sep 30, 2024 -111.11 Mn
Jun 30, 2024 -83.48 Mn
Jun 30, 2024 -83.48 Mn
Mar 31, 2024 -17.87 Mn
Mar 31, 2024 -17.87 Mn
Dec 31, 2023 -276.50 Mn
Dec 31, 2023 -276.50 Mn